Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBreast CancerCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR+ Lung CancerFollicular LymphomaGI CancersHCCHER2-Positive Breast CancerLung CancerLymphomasMantle Cell LymphomaMPNsMultiple MyelomaProstate CancerRenal Cell CarcinomaThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
News
Conferences
Conference CoverageConference Listing
Media
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
Publications
All PublicationsCBR SpotlightEvolving ParadigmsTargeted Therapies in Oncology
CME/CE
Resources
PartnersPress Releases
Subscribe
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Breast Cancer
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR+ Lung Cancer
  • Follicular Lymphoma
  • GI Cancers
  • HCC
  • HER2-Positive Breast Cancer
  • Lung Cancer
  • Lymphomas
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Prostate Cancer
  • Renal Cell Carcinoma
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Donnellan Promoted to Director of Leukemia at Sarah Cannon

June 28, 2018

William B. Donnellan, MD, was recently promoted to director of Leukemia/Myelodysplastic Syndrome Research at the Sarah Cannon Research Institute in Nashville, Tennessee. Donnellan has served as an investigator of hematologic malignancies since 2014 at the Sarah Cannon Research Institute.

William B. Donnellan, MD

William B. Donnellan, MD, was recently promoted to director of Leukemia/Myelodysplastic Syndrome (MDS) Research at the Sarah Cannon Research Institute in Nashville, Tennessee. Donnellan has served as an investigator of hematologic malignancies since 2014 at the Sarah Cannon Research Institute. He specializes in treating patients with various blood cancers, with a special interest in myeloid stem cell disorders.

Donnellan will oversee research in myeloid stem cell disorders in his new role as director. Research will focus on malignancies including MDS, acute myeloid leukemia, and myeloproliferative neoplasms.

Recently, he was the lead author of a small phase II trial evaluating a dose-escalating, infusion regimen of ofatumumab (Arzerra) in patients with previously treated chronic lymphocytic leukemia. Using the stepped-up dosing regimen, the rapid infusion of ofatumumab was found to be safe and well tolerated.

“Dr Donnellan has played an integral role in advancing research for blood cancers and ensuring patients facing the disease are receiving the best possible care,” said David Spigel, MD, the chief scientific officer at Sarah Cannon.

Board certified in internal medicine, hematology, and medical oncology, Donnellan also serves as an associate with Tennessee Oncology, PLLC. He received his undergraduate degree from Auburn University and his medical degree from the University of Alabama School of Medicine, where he also completed his residency.

Donnellan was awarded the C. Glenn Cobbs Award for excellence at the Birmingham VA Medical Center. He also received the Claude Bennett Award for outstanding performance at University Hospital. Additionally, he completed a fellowship at the University of Alabama in hematology/oncology. His special focus was in blood and marrow transplantation.

Additionally, he has professional memberships with the American Society of Clinical Oncology and the American Society of Hematology.